Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $85 | $11 |
| % Growth | -53.1% | -99.8% | 695.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $85 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $172 | $183 | $159 | $139 |
| G&A Expenses | $52 | $67 | $117 | $89 |
| SG&A Expenses | $52 | $67 | $117 | $89 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $135 | -$3 | -$5 | -$2 |
| Operating Expenses | $359 | $247 | $272 | $225 |
| Operating Income | -$359 | -$247 | -$187 | -$215 |
| % Margin | -588,123% | -190,006.2% | -220.9% | -2,016.7% |
| Other Income/Exp. Net | $16 | $12 | $4 | -$35 |
| Pre-Tax Income | -$343 | -$235 | -$183 | -$250 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$343 | -$235 | -$183 | -$250 |
| % Margin | -562,285.2% | -180,486.2% | -216.2% | -2,349.5% |
| EPS | -1.31 | -0.935 | -0.741 | -1.031 |
| % Growth | -40.1% | -26.1% | 28.1% | – |
| EPS Diluted | -1.31 | -0.935 | -0.741 | -1.031 |
| Weighted Avg Shares Out | 13 | 13 | 12 | 12 |
| Weighted Avg Shares Out Dil | 13 | 13 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $24 | $23 | $7 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $20 | $20 | $18 | $14 |
| EBITDA | -$201 | -$227 | -$169 | -$201 |
| % Margin | -328,923% | -174,429.2% | -199.6% | -1,888.8% |